The joining up of corporate venturing units into the broader innovation toolkits of companies, including M&A, will increasingly be important next year.
Boehringer Ingelheim Venture Fund’s (BIVF), the corporate venturing affiliate of the eponymous Germany-based pharmaceutical company, announcement this week to set up an office in the Boston region of the US offers an insight into the future of the industry.
Beyond the international angle as corporations set up across borders to tap into innovation hotspots, just as many venture capital firms retreat back to one location, is certainly one trend.
A second is the attention to why Boston is an innovation…
